CLDX Q2 2017 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+175.7% YoY

Gross Profit

-$21M-552.9% margin

Operating Income

-$29M-755.5% margin

Net Income

-$29M-746.0% margin

EPS (Diluted)

$-3.42

QoQ Revenue Growth

+149.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$346M

Total Liabilities

$115M

Stockholders' Equity

$231M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$1M	+175.7%
Gross Profit	-$21M	-$48M	+56.1%
Operating Income	-$29M	-$32M	+10.6%
Net Income	-$29M	-$32M	+10.6%